Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LNO-301
- Development stage
- Preclinical
- Lead developer
- Linno Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
LNO-301 is a preclinical-stage transdermal patch candidate being developed by Linno Pharmaceuticals (also known as Lingnuo Pharmaceuticals) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The program utilizes a transdermal delivery system designed to provide sustained release of the active medication through the skin, which may offer advantages such as a more stable pharmacokinetic profile and improved patient compliance compared to traditional oral ADHD therapies. As of current reporting, the specific active pharmaceutical ingredient (API) and its exact molecular target have not been publicly disclosed by the sponsor.
Beyond the preview
Go deeper on LNO-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNO-301.